Company Overview and News

 
INNATE PHARMA : Données préliminaires d'activité de la combinaison monalizumab et durvalumab dans le cancer colorectal

2018-05-17 globenewswire
DES DONNÉES PRÉLIMINAIRES D'UN ESSAI DE PHASE I ÉVALUANT MONALIZUMAB ET IMFINZI® (DURVALUMAB) MONTRENT UNE ACTIVITÉ ANTI-TUMORALE CHEZ DES PATIENTS PRÉSENTANT UN CANCER COLORECTAL

 
INNATE PHARMA : Preliminary activity observed of the combination of monalizumab and durvalumab in patients with colorectal cancer

2018-05-17 globenewswire
preliminary DATA from a phase I dose escalation and expansion study of monalizumab and Imfinzi® (durvalumab) SHOW ANTI-TUMOR activity in COLORECTAL CANCER patients

 
INNATE PHARMA : First quarter 2018 report

2018-05-16 globenewswire
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announced its revenues and cash position for the first three months of 2018.

 
INNATE PHARMA : Information financière du premier trimestre 2018

2018-05-16 globenewswire
Innate Pharma SA (La « Société » - Euronext Paris : FR0010331421 - IPH) annonce aujourd'hui son chiffre d'affaires et sa trésorerie pour les trois premiers mois de l'année 2018.

 
Reader Inquiry: Is InflaRx A Buy On The Dip?

2018-05-13 seekingalpha
At one point shares nearly tripled from their IPO price and have risen by over 60% year to date.

 
Innate Pharma annonce la tenue de son AG annuelle le 29 mai 2018 et la mise à disposition de son DDR 2017

2018-04-30 globenewswire
INNATE PHARMA ANNONCE LA TENUE DE SON ASSEMBLEE GENERALE ANNUELLE LE 29 MAI 2018 A MARSEILLE ET LA MISE A DISPOSITION DE SON DOCUMENT DE REFERENCE 2017

 
Innate Pharma to hold its AGM on May 29, 2018 and the release of its Reference document

2018-04-30 globenewswire
Innate pharma TO hold ITS annual general meeting of shareholders on May 29, 2018 and THE RELEASE OF ITS REFERENCE DOCUMENT (IN FRENCH)

 
INNATE PHARMA : Données préliminaires d'activité prometteuses pour la combinaison monalizumab et cetuximab dans le SCCHN

2018-04-17 globenewswire
DONNÉES PRÉLIMINAIRES D'ACTIVITÉ PROMETTEUSES POUR LA COMBINAISON DE MONALIZUMAB ET CETUXIMAB CHEZ DES PATIENTS ATTEINTS D'UN CANCER DE LA TÊTE ET DE COU ET PRÉTRAITÉS PAR SELS DE PLATINE

 
INNATE PHARMA : Promising anti-tumor activity of monalizumab with cetuximab in SCCHN

2018-04-17 globenewswire
preliminary data suggest promising anti-tumor activity of the combination of monalizumab and cetuximab in patients with platinum pretreated SCCHN

 
INNATE PHARMA : AACR 2018 Nouvelles données précliniques renforçant le rationnel des programmes en cours

2018-04-17 globenewswire
Innate Pharma SA (la « Société » - Euronext Paris : FR0010331421 - IPH) a présenté de nouvelles données précliniques de son portefeuille innovant d'immunothérapies au congrès annuel de l'Association Américaine pour la Recherche sur le Cancer (AACR[*] - 14 au 18 avril, Chicago).

 
INNATE PHARMA : AACR 2018, New preclinical data further support ongoing programs

2018-04-17 globenewswire
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) announces that new preclinical data of the Company's broad and innovative portfolio of next generation immunotherapies have been presented at the American Association for Cancer Research (AACR) Annual Meeting, April 14-18, in Chicago.

 
INNATE PHARMA : Prochains rendez-vous investisseurs

2018-04-09 globenewswire
Innate Pharma SA (Euronext Paris : FR0010331421 - IPH) annonce aujourd'hui qu'elle sera présente aux événements investisseurs suivants :

 
INNATE PHARMA : Upcoming investor conferences

2018-04-09 globenewswire
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announces that it will be present at the following investor events:

 
INNATE PHARMA : Expansion of mCRC cohort in Phase I trial evaluating monalizumab with Imfinzi

2018-03-23 globenewswire
Partner MedImmune expands colorectal cancer patient cohort in ongoing PHASE I TRIAL EVALUATING MONALIZUMAB IN COMBINATION WITH IMFINZI® (DURVALUMAB)

 
INNATE PHARMA : Extension de cohorte dans la Phase I évaluant monalizumab et Imfinzi dans le cancer colorectal

2018-03-23 globenewswire
MedImmune Étend l'essai de phase I en cours Évaluant MONALIZUMAB en combinaison avec Imfinzi® (DURVALUMAB) et inclut de nouvelles cohortes de patients atteints d'un cancer colorectal

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

12h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

12h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

22h - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...